Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir

Journal of Infectious Diseases

Volumn 203, Issue 7, 2011, Pages 937-942

  Shi, Deshi ^a,b   Yang, Dongfang ^a   Prinssen, Eric P ^b,c   Davies, Brian E ^c,d   Yan, Bingfang ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 1; MESSENGER RNA; OSELTAMIVIR; PRODRUG; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG ACTIVATION; DRUG HYDROLYSIS; DRUG TISSUE LEVEL; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; INFANT; LIVER; NUCLEOTIDE SEQUENCE; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADOLESCENT; ADULT; AGE FACTORS; ANTIVIRAL AGENTS; CARBOXYLIC ESTER HYDROLASES; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; LIVER; OSELTAMIVIR; PRODRUGS; YOUNG ADULT;

EID: 79953002418     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq145     Document Type: Article

References (26)

1. Satoh T, Hosokawa M. Structure, function and regulation of carboxylesterases. Chem Biol Interact 2006; 162:195-211. (Pubitemid 44402409)
2. Sanghani SP, Sanghani PC, Schiel MA, Bosron WF. Human carboxylesterases: an update on CES1, CES2 and CES3. Protein Pept Lett 2009; 16:1207-14.
3. Yang D, Wang X, Yang D, Yan B. Pyrethroid insecticides: isoform-dependent hydrolysis, induction of cytochrome P450 3A4 and evidence on the involvement of the pregnane X receptor. Toxicol Appl Pharmacol 2009; 237:49-58.
4. Crow JA, Middleton BL, Borazjani A, Hatfield MJ, Potter PM, Ross MK. Inhibition of carboxylesterase 1 is associated with cholesteryl ester retention in human THP-1 monocyte/macrophages. Biochim Biophys Acta 2008; 1781:643-54.
5. Wei E, Alam M, Sun F, Agellon LB, Vance DE, Lehner R. Apolipoprotein B and triacylglycerol secretion in human triacylglycerol hydrolase transgenic mice. J Lipid Res 2007; 48:2597-606. (Pubitemid 350272844)
6. Tang M, Mukundan M, Yang J, et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 2006; 319:1467-76.
7. Sanghani SP, Quinney SK, Fredenburg TB, DavisWI, Murry DJ, Bosron WF. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5- aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos 2004; 32:505-11. (Pubitemid 38535028)
8. Shi D, Yang J, Yang D, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase HCE1 and the activation is inhibited by anti-platelet agent clopidogrel. J Pharmacol Exp Ther 2006;319:1477-84.
9. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis 2010; 202:1154-60.
10. Lee VJ, Yap J, Cook AR, et al. Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. N Engl J Med 2010;362:2166-74.
11. Acosta EP, Jester P, Gal P, et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis 2010; 202:563-6.
12. Siedler K, Skopnik H. Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis. Pediatr Infect Dis J 2010;29:495-8.
13. Yang D, Pearce R, Wang X, Gaedigk R, Wan YJY, Yan B. Human carboxylesterases HCE1 and HCE2: ontogenic expression, interindividual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 2009; 77:238-47.
14. Yang J, Shi D, Yang D, Song X, Yan B. Interleukin-6 suppresses the expression of carboxylesterases HCE1 and HCE2 through transcriptional repression. Mol Pharmacol 2007; 72:686-94. (Pubitemid 47347303)
15. Hosokawa M, Furihata T, Yaginuma Y, et al. Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes. Drug Metab Pharmacokinet 2008; 23:73-84.
16. Zhu W, Song L, Zhang H, Matoney L, LeCluyse E, Yan B. Dexamethasone differentially regulates the expression of carboxylesterase genes in humans and rats. Drug Metab Dispos 2000; 28:186-91. (Pubitemid 30069003)
17. Shi D, Yang J, Yang D, You L, Yan B. Dexamethasone suppresses the expression of multiple rat carboxylesterases through transcriptional repression: evidence for an involvement of the glucocorticoid receptor. Toxicology 2008; 254:97-105.
18. Zhu HJ, Appel DI, Jiang Y, Markowitz JS. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos 2009; 37:1819-25.
19. Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab 2010; 11:206-12.
20. Morgan EW, Yan B, Greenway D, Parkinson A. Regulation of two rat liver microsomal carboxylesterase isozymes: species differences, tissue distribution and the effects of age, sex and xenobiotic treatment of rats. Arch Biochem Biophys 1994; 315:514-26.
21. Hosokawa M, Hirata K, Nakata F, Suga T, Satoh T. Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethylhexyl)phthalate, a peroxisome proliferator. Drug Metab Dispos 1994; 22:889-94. (Pubitemid 24377364)
22. Poole M, Bridgers K, Alexson SE, Corton JC. Altered expression of the carboxylesterases ES-4 and ES-10 by peroxisome proliferator chemicals. Toxicology 2001; 165:109-19. (Pubitemid 32778304)
23. Hosokawa M, Satoh T. Effects of hypophysectomy and pituitary hormones on hepatic microsomal carboxylesterase isozymes in male rats. Res Commun Chem Pathol Pharmacol 1988; 62:279-88. (Pubitemid 19008046)
24. Zhu HJ, Markowitz JS. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos 2009; 37:264-7.
25. Massarella JW, He GZ, Dorr A, Nieforth K, Ward P, Brown A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 2000; 40:836-43.
26. Holodniy M, Penzak SR, Straight TM, et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother 2008; 52:3013-21.